Perdagangan Vir Biotechnology VIR

VirBiotechnology diagram langsung

Dasar-dasar Instrumen

Weekly Search
Weekly
Daily
Tanggal Tutup Ubah Ubah (%) Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tampilkan lebih banyak
Ghko B 2025 Jul 28, 16:00

VAPE Stock Soars 600%: What’s Happening with CEA Industries?

Stocks
Frances Wang 2025 Jul 28, 16:00

DJT Stock Dips: What’s Going on with Trump Media?

Stocks
Frances Wang 2025 Jul 27, 16:00

Trending Stocks Today: PLTR Stock , MCVT Stock, SMCI Stock, NVDA Stock

Stocks
Interest rate cut percentage
Tommy Yap 2025 Jul 26, 21:00

Week Ahead: Interest Rate Decisions from Fed, BoC, and BoJ in Focus

Forex Indices
Liam James 2025 Jul 25, 10:20

ECB Rate Cut Expectations Revised Amid Economic Resilience

Ava Grace 2025 Jul 25, 09:20

Hedge Funds Advise Buying Protection Against Potential Stock Market Downturn

Liam James 2025 Jul 25, 08:20

Federal Funds Rate vs. SOFR: Liquidity Measurement Debate in US Financial System

Ava Grace 2025 Jul 25, 07:20

Musk Praises Tesla Autopilot Performance in China Test, Sparking Debate

Info

Spread

0.05

Spread (%)

0.9208 %

Leverage

1:10

Bunga Overnight Beli

-0.0597 %

Bunga Overnight Jual

-0.0292 %

Mata Uang

USD

Jam Trading

Pasar tutup

Selasa

13:31 - 19:59

Senin

13:31-19:59

Rabu

13:31-19:59

Kamis

13:31-19:59

Jumat

13:31-19:59

Analisis dan Statistik

Buka

---

Sebelumnya Tutup

---

52 Minggu Tigg/Rdh

--- – ---

Kapitalisasi Pasar

781044736

Saham yang Beredar

138238000

Tanggal Penghasilan (Berikutnya)

0000-00-00

Hasil Div

Tanggal Non-Dividen

Proyeksi tingkat dividen tahunan

0

Proyeksi hasil dividen tahunan

0

EPS

-4.23

Pelajari lebih lanjut tentang instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

Tampilkan lebih banyak
Trustpilot